An observational study in HIV, Menopause and Cardiovascular (CV) Risk, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Carotid Artery Diseases with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Carotid Artery Diseases · United States.
Among the 77 studies in Carotid Artery Diseases with a site in United States, this one is the 26th largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2026, is one of 34 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 73rd registered.
260 studies on the registry are indexed under Carotid Artery Diseases; 60 are open to participants now.
Browse Carotid Artery Diseases studies →15 of the 77 studies in Carotid Artery Diseases with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Shockwave Medical, Inc. · Sites in United States
Ages 18+
Intervascular · Sites in United States, Belgium, France and 1 more country
Ages 18+
Colorado Prevention Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Carotid Artery Diseases studies recruiting now, 33 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 200 across 115 observational studies indexed under Carotid Artery Diseases.
Median enrollment 210 across the 43 interventional studies, 211 across the 34 observational. Of the 51 that completed or were terminated, 22 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 77 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 1 study filed under Carotid Artery Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Carotid Artery Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02240862University of Maryland, BaltimoreThe CREST-2 Registry | 2026-12-31 |
| NCT02850588Society for Vascular Surgery Patient Safety OrganizationSVS VQI TransCarotid Revascularization Surveillance Project | 2026-12-31 |
| NCT07334834Colorado Prevention CenterImplementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease | 2027-05 |
| NCT07916883Washington University School of MedicinePET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite) | 2027-05-31 |
| NCT05838547Washington University School of MedicineCANF-Comb-II PET-MR in Atherosclerosis Multisite | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Carotid Artery Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.
Women with HIV who are enrolled in the MWCCS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Whole body MRI
Whole body MRI will be performed as part of a study protocol
Markers of immune activation and inflammation
sCD14 (monocyte activation), sCD163 (M2 macrophage activation), CRP (inflammation), IL-6 (inflammation), IP-10 (interferon-inducible protein), TNFα (inflammation), MCP-1 (inflammation), sTNFRI \& RII (inflammation). There are no units as they will be normalized based upon their interquartile range.
Time frame: These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 46 months after the start.
Of 45 observational studies under Carotid Artery Diseases, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 94. This study's planned 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →